Mycoplasma genitalium (M. genitalium) is a STI of rising concern due to its increasing prevalence and the current hurdles concerning antbiotic resistance. As a firm engaged in the vaccine and therapy development, along with strong preclinical development services capability, we are well placed to mitigate the threat that this pathology poses.
Overview of Mycoplasma Genitalium Infection
Mycoplasma genitalium is a contagion with medical concern that has been around for some time, especially now during this time of history. The fastidious bacterium, being one of the self-replicating organisms, is one of the tiniest organisms and because of its biology it has no cell wall which makes it impervious to antibiotics that target the cell wall structure. M. Genitalium is a type of urethritis and has been refined to include some infections of the reproductive tract in men which include cervicitis, pelvic inflammatory disease and tubal factor fertility in women.
Fig.1 Mycoplasma genitalium structure and interactions with human reproductive tract epithelial cells. (McGowin C. L., et al., 2017)
Vaccine Development for Mycoplasma Genitalium Infection
Multi-Epitope Subunit Vaccines
Multi epitope subunit vaccines consist of several B and T cell epitopes derived from multi epitope subunit vaccines whereby the immunogenicity is enhanced.
DNA vaccines use plasmids that encode Mycoplasma genitalium antigens. These plasmids are taken up by overlapping inoculations, and once inside the cell, they create immunogenic proteins which evoke immune responses.
While having certain safety concerns attached to them and hence being relatively unconventional, live attenuated vaccines might offer a very strong and persistent immunity owing to the natural infection they imitate.
Therapeutics Development for Mycoplasma Genitalium Infection
To debut, macrolide antibiotics like azithromycin used to be the fundamentals of treating Mycoplasma genitalium but with the new resistant strains surfacing, the use of macrolides are taken with caution, thus the look for other therapeutics options began.
Recombinant therapy for Mycoplasma genitalium treatment is on the rise with the use of zephyr azythromycins, solithromycins, and sitafloxacins, which are at different trial levels but target the resistant strains. These medications look promising for the treatment of resistant strains targeting ant bacterial agents.
Our Services
Fueled by our creative vaccine production strategies, breakthrough therapeutic approaches and advanced preclinical studies, we give you bespoke options that cater to your needs.
Disease Models
- M. genitalium Urogenital Infection: Mice, Hamsters, and Rhesus Monkeys
- Cervical Inoculation with M. genitalium: Pig-Tailed Macaques
- Intraoviduct Inoculation: Marmosets and Grivet Monkeys
Preclinical Research
- Drug Safety Evaluation
- In Vivo Pharmacokinetics Study
- In Vitro Pharmacokinetics Study
- Activity Testing
- Drug Resistance Evaluation
In order to aid our development of vaccines and therapies, we have set about building a detailed range of animal models for the M. genitalium infection. These unique prototypes of non human primates as well as rodent and tissue based models allow for further pathogenesis studies of the infection as well as mediating studies and drug and vaccine candidate evaluations. Should our services interest you, we invite you to contact us for further details and to get a quote for the services that you need.
References
- McGowin, Chris L., and Patricia A. Totten. "The unique microbiology and molecular pathogenesis of Mycoplasma genitalium." The Journal of infectious diseases 216.suppl_2 (2017): S382-S388.
- Sethi, Sunil, Kamran Zaman, and Neha Jain. "Mycoplasma genitalium infections: current treatment options and resistance issues." Infection and drug resistance (2017): 283-292.
- Ali, Sharafat, et al. "Proteome wide vaccine targets prioritization and designing of antigenic vaccine candidate to trigger the host immune response against the Mycoplasma genitalium infection." Microbial Pathogenesis 152 (2021): 104771.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
